| Product Code: ETC9979913 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) mRNA Vaccine and Therapeutics Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) mRNA Vaccine and Therapeutics Market - Industry Life Cycle |
3.4 United States (US) mRNA Vaccine and Therapeutics Market - Porter's Five Forces |
3.5 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume Share, By Vaccine Type, 2021 & 2031F |
3.6 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.8 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume Share, By End user, 2021 & 2031F |
4 United States (US) mRNA Vaccine and Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of infectious diseases and pandemics driving the demand for mRNA vaccines and therapeutics |
4.2.2 Technological advancements in mRNA technology leading to the development of more effective and targeted treatments |
4.2.3 Growing investments in research and development by pharmaceutical companies and government agencies to support mRNA vaccine and therapeutics development |
4.3 Market Restraints |
4.3.1 High manufacturing costs associated with mRNA vaccines and therapeutics impacting affordability and accessibility |
4.3.2 Regulatory challenges and approval processes for mRNA-based products delaying market entry and commercialization |
4.3.3 Concerns around long-term safety and efficacy of mRNA vaccines and therapeutics limiting widespread adoption |
5 United States (US) mRNA Vaccine and Therapeutics Market Trends |
6 United States (US) mRNA Vaccine and Therapeutics Market, By Types |
6.1 United States (US) mRNA Vaccine and Therapeutics Market, By Vaccine Type |
6.1.1 Overview and Analysis |
6.1.2 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Vaccine Type, 2021- 2031F |
6.1.3 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Self-amplifying mRNA-based Vaccines, 2021- 2031F |
6.1.4 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Conventional Non-amplifying mRNA-based Vaccines, 2021- 2031F |
6.2 United States (US) mRNA Vaccine and Therapeutics Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Cancer, 2021- 2031F |
6.2.3 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Infectious Diseases, 2021- 2031F |
6.2.4 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Autoimmune Diseases, 2021- 2031F |
6.2.5 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Other, 2021- 2031F |
6.3 United States (US) mRNA Vaccine and Therapeutics Market, By Treatment Type |
6.3.1 Overview and Analysis |
6.3.2 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Monoclonal Antibody, 2021- 2031F |
6.3.3 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Gene Therapy, 2021- 2031F |
6.3.4 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Cell Therapy, 2021- 2031F |
6.3.5 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Other, 2021- 2031F |
6.4 United States (US) mRNA Vaccine and Therapeutics Market, By End user |
6.4.1 Overview and Analysis |
6.4.2 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Research Laboratories and Organizations, 2021- 2031F |
6.4.3 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.4 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.5 United States (US) mRNA Vaccine and Therapeutics Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) mRNA Vaccine and Therapeutics Market Import-Export Trade Statistics |
7.1 United States (US) mRNA Vaccine and Therapeutics Market Export to Major Countries |
7.2 United States (US) mRNA Vaccine and Therapeutics Market Imports from Major Countries |
8 United States (US) mRNA Vaccine and Therapeutics Market Key Performance Indicators |
8.1 Research and development investment in mRNA technology advancements |
8.2 Number of clinical trials and pipeline development for mRNA vaccines and therapeutics |
8.3 Adoption rate of mRNA-based treatments in healthcare settings |
9 United States (US) mRNA Vaccine and Therapeutics Market - Opportunity Assessment |
9.1 United States (US) mRNA Vaccine and Therapeutics Market Opportunity Assessment, By Vaccine Type, 2021 & 2031F |
9.2 United States (US) mRNA Vaccine and Therapeutics Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 United States (US) mRNA Vaccine and Therapeutics Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
9.4 United States (US) mRNA Vaccine and Therapeutics Market Opportunity Assessment, By End user, 2021 & 2031F |
10 United States (US) mRNA Vaccine and Therapeutics Market - Competitive Landscape |
10.1 United States (US) mRNA Vaccine and Therapeutics Market Revenue Share, By Companies, 2024 |
10.2 United States (US) mRNA Vaccine and Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |